Enhancing the QUAlity and Transparency Of health Research
Medical Publishing Insights and Practices (MPIP), the International Society for Medical Publication Professionals and representatives from the pharmaceutical industry have recently published guidelines to encourage clinically relevant and more informative adverse event reporting in clinical trial publications. The reporting guideline provides five consensus recommendations which supplement the guidance contained in the CONSORT Harms Extension.
Lineberry N, Berlin JA, Mansi B, Glasser S, Berkwits M, Klem C, Bhattacharya A, Citrome L, Enck R, Fletcher J, Haller D, Chen TT, Laine C. Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. BMJ. 2016;355:i5078.
The new guideline can be accessed at: adverse event reporting
How can reporting quality interfere with reproducibility issues and overall trust in science results? With that question in mind, we participated in the Reproducibility, Replicability and Trust in Science conference organised by the Wellcome Genome Campus from 9 to 11...